Radiopharm Theranostics Highlights 90% Positive RAD101 Interim Data, Eyes Phase III FDA Talks [Yahoo! Finance]
Radiopharm Theranostics Limited - American Depositary Shares (RADX)
Company Research
Source: Yahoo! Finance
is 27/30 with a full readout expected in May–June and an FDA meeting planned around June to discuss a Phase III registrational design. All four therapeutic programs (RAD204, RAD202, BetaBart, KLK3) are in the clinic with continued dose escalation, early signs of tumor uptake and no major safety signals reported, and the company expects RAD204 and RAD202 Phase I readouts before year-end and further portfolio readouts through 2026 while positioning several assets as first-in-class. Interested in Radiopharm Theranostics Limited - Sponsored ADR? Here are five stocks we like better. Radiopharm Theranostics (NASDAQ:RADX) provided an update on its clinical-stage radiopharmaceutical pipeline during an investor conference presentation led by CEO Riccardo Canevari, highlighting interim results from its lead imaging program and progress across four therapeutic candidates in human trials. RAD101 interim data in brain metastases trial Canevari focused first on RAD101, the company's lead
Show less
Read more
Impact Snapshot
Event Time:
RADX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RADX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RADX alerts
High impacting Radiopharm Theranostics Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
RADX
News
- Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate CancerGlobeNewswire
- Radiopharm Theranostics Shares RAD101 Phase IIb Update: 90% Hit Primary Endpoint in Brain Mets Study [Yahoo! Finance]Yahoo! Finance
- Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain MetastasesGlobeNewswire
- Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)GlobeNewswire
- RADX Fiscal 1H:26 Activity and Cash Flows [Yahoo! Finance]Yahoo! Finance
RADX
Sec Filings
- 4/1/26 - Form 3
- 4/1/26 - Form 3
- 3/31/26 - Form 3
- RADX's page on the SEC website